ArticleEMBO molecular medicine2026

JAK1/2 inhibitor ruxolitinib reduces aggregates in cardiac proteinopathy.

Erda Alizoti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.